PKC-activating compounds for the treatment of neurodegenerative diseases
AssigneeSynaptogenix, Inc.
InventorsThomas J. Nelson, Daniel L. Alkon
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Claims6
A method of treating multiple sclerosis, comprising administering to a patient in need thereof an effective amount of an epoxidized polyunsaturated fatty acid (PUFA) ester wherein at least one carbon-carbon unsaturated bond in said PUFA is epoxidized, wherein the epoxidized polyunsaturated fatty acid (PUFA) ester has any of the following formulas:
- CH3(CH2)4(CH═CHCH2)x(CH2)yCOOR or CH3CH2(CH═CHCH2)x(CH2)yCOOR, wherein x is 2-6, y is 2-6, and R is alkyl, wherein at least one carbon-carbon unsaturated bond in said epoxidized PUFA is epoxidized.
Dependencies are inferred from the claim text.